BioLife Solutions, Inc. (NASDAQ:BLFS – Get Rating) CMO Todd Berard sold 6,500 shares of the company's stock in a transaction dated Wednesday, January 18th. The stock was sold at an average price of $25.04, for a total value of $162,760.00. Following the sale, the chief marketing officer now owns 119,265 shares in the company, valued at approximately $2,986,395.60. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
Todd Berard also recently made the following trade(s):
Get BioLife Solutions alerts:- On Wednesday, December 28th, Todd Berard sold 501 shares of BioLife Solutions stock. The stock was sold at an average price of $16.90, for a total value of $8,466.90.
- On Thursday, November 10th, Todd Berard sold 50 shares of BioLife Solutions stock. The shares were sold at an average price of $23.16, for a total value of $1,158.00.
BioLife Solutions Trading Up 2.4 %
NASDAQ:BLFS opened at $24.45 on Monday. The stock's 50 day moving average price is $20.35 and its 200 day moving average price is $21.18. The company has a market capitalization of $1.05 billion, a PE ratio of -9.86 and a beta of 1.75. The company has a quick ratio of 2.76, a current ratio of 3.68 and a debt-to-equity ratio of 0.06. BioLife Solutions, Inc. has a 52-week low of $10.40 and a 52-week high of $31.11.
BioLife Solutions (NASDAQ:BLFS – Get Rating) last released its quarterly earnings results on Wednesday, November 9th. The medical equipment provider reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.03). The firm had revenue of $40.75 million for the quarter, compared to analysts' expectations of $41.63 million. BioLife Solutions had a negative return on equity of 7.50% and a negative net margin of 67.70%. On average, research analysts anticipate that BioLife Solutions, Inc. will post -0.63 EPS for the current year.Institutional Trading of BioLife Solutions
A number of hedge funds have recently added to or reduced their stakes in the stock. Public Sector Pension Investment Board lifted its position in BioLife Solutions by 1.0% during the 2nd quarter. Public Sector Pension Investment Board now owns 56,525 shares of the medical equipment provider's stock worth $781,000 after acquiring an additional 565 shares during the period. Texas Permanent School Fund lifted its position in BioLife Solutions by 3.0% during the 2nd quarter. Texas Permanent School Fund now owns 21,901 shares of the medical equipment provider's stock worth $302,000 after acquiring an additional 642 shares during the period. Macquarie Group Ltd. lifted its position in BioLife Solutions by 1.1% during the 2nd quarter. Macquarie Group Ltd. now owns 73,437 shares of the medical equipment provider's stock worth $1,014,000 after acquiring an additional 766 shares during the period. Mutual of America Capital Management LLC lifted its position in BioLife Solutions by 18.7% during the 2nd quarter. Mutual of America Capital Management LLC now owns 5,128 shares of the medical equipment provider's stock worth $71,000 after acquiring an additional 808 shares during the period. Finally, Jane Street Group LLC lifted its position in BioLife Solutions by 6.9% during the 1st quarter. Jane Street Group LLC now owns 13,377 shares of the medical equipment provider's stock worth $304,000 after acquiring an additional 858 shares during the period. 89.82% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of research analysts have recently commented on BLFS shares. Stephens dropped their price objective on BioLife Solutions to $31.00 in a report on Wednesday, November 16th. StockNews.com upgraded BioLife Solutions to a "sell" rating in a report on Monday, November 21st.
BioLife Solutions Company Profile
(Get Rating)
BioLife Solutions, Inc develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
Further Reading
- Get a free copy of the StockNews.com research report on BioLife Solutions (BLFS)
- CVS Health is Growing into an Integrated Healthcare Organization
- NVIDIA Outlook Improving: Watchlist Candidate for 2023
- Is C3.ai Stock a ChatGPT Artificial Intelligence Play?
- Which Wireless Stock Should You Buy in 2023?
- Is Virgin Galactic Stock Preparing for Lift-Off?
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.